Syros Pharmaceuticals Inc (NASDAQ: SYRS) has seen a decline in its stock price by -15.54 in relation to its previous close of 0.26. However, the company has experienced a -93.22% decline in its stock price over the last five trading sessions. zacks.com reported 2024-11-14 that SYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.
Is It Worth Investing in Syros Pharmaceuticals Inc (NASDAQ: SYRS) Right Now?
Company’s 36-month beta value is 1.50.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SYRS is 16.89M, and currently, short sellers hold a 7.39% ratio of that floaft. The average trading volume of SYRS on November 18, 2024 was 1.44M shares.
SYRS’s Market Performance
SYRS’s stock has seen a -93.22% decrease for the week, with a -88.83% drop in the past month and a -87.41% fall in the past quarter. The volatility ratio for the week is 26.23%, and the volatility levels for the past 30 days are at 16.34% for Syros Pharmaceuticals Inc The simple moving average for the past 20 days is -89.15% for SYRS’s stock, with a -95.08% simple moving average for the past 200 days.
Analysts’ Opinion of SYRS
Many brokerage firms have already submitted their reports for SYRS stocks, with H.C. Wainwright repeating the rating for SYRS by listing it as a “Buy.” The predicted price for SYRS in the upcoming period, according to H.C. Wainwright is $15 based on the research report published on November 04, 2020 of the previous year 2020.
Alliance Global Partners, on the other hand, stated in their research note that they expect to see SYRS reach a price target of $18. The rating they have provided for SYRS stocks is “Buy” according to the report published on September 22nd, 2020.
SYRS Trading at -88.86% from the 50-Day Moving Average
After a stumble in the market that brought SYRS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.32% of loss for the given period.
Volatility was left at 16.34%, however, over the last 30 days, the volatility rate increased by 26.23%, as shares sank -90.10% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -85.22% lower at present.
During the last 5 trading sessions, SYRS fell by -93.14%, which changed the moving average for the period of 200-days by -97.10% in comparison to the 20-day moving average, which settled at $2.0190. In addition, Syros Pharmaceuticals Inc saw -97.19% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SYRS starting from Chee Conley, who purchase 50,000 shares at the price of $1.71 back on Sep 11 ’24. After this action, Chee Conley now owns 122,504 shares of Syros Pharmaceuticals Inc, valued at $85,420 using the latest closing price.
Haas Jason, the Chief Financial Officer of Syros Pharmaceuticals Inc, purchase 45,344 shares at $1.68 during a trade that took place back on Sep 12 ’24, which means that Haas Jason is holding 124,552 shares at $76,006 based on the most recent closing price.
Stock Fundamentals for SYRS
Current profitability levels for the company are sitting at:
- -288.92 for the present operating margin
- -2.29 for the gross margin
The net margin for Syros Pharmaceuticals Inc stands at -253.41. The total capital return value is set at -1.97. Equity return is now at value -776.96, with -84.04 for asset returns.
Based on Syros Pharmaceuticals Inc (SYRS), the company’s capital structure generated 1.34 points at debt to capital in total, while cash flow to debt ratio is standing at -2.29. The debt to equity ratio resting at -3.93. The interest coverage ratio of the stock is -20.92.
Currently, EBITDA for the company is -157.19 million with net debt to EBITDA at -0.02. When we switch over and look at the enterprise to sales, we see a ratio of 20.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.25.
Conclusion
In a nutshell, Syros Pharmaceuticals Inc (SYRS) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
